• 分类：最新消息
• 作者：华讯知识产权
• 来源：
• 发布时间：2020-11-20 13:53
• 访问量：

【概要描述】Affected by the COVID-19, global IPO activity slows down in 2020. But this year is a glorious year for China's biomedical companies. Since 2018, the Hong Kong Exchanges and Clearing Limited (HKEx) has opened its doors for the first time to biotechnology companies that have no operating income. In 2019, The Science and Technology Innovation Board (STAR Market) established by the Shanghai Stock Exchange has been officially opened for trading. It has brought new vitality to China's capital market and the development of China's technology.. The HKEx and STAR Market have become the first choice for many Chinese unprofitable biomedical companies to list. According to incomplete statistics, as of Nov 20, at least 13 Chinese biopharmaceutical companies have been listed on the HKEx and 10 companies have been listed on the STAR Market. See the table below for details:   S/N Company name Stock Exchange Capital Raised Business area 1 Akeso,Inc HKEx Over $300 million Tumour、Autoimmune disease 2 Innocare HKEx About HK$2.093 billion Cancer、Autoimmune disease 3 Kintor Pharmaceutical Limited HKEx About $240 million Prostate Cancer、Breast Cancer Liver cancer、Baldness 4 Zai Lab Limited HKEx HK$5.73 billion Tumour、Autoimmune disease 5 Immunotech Biopharm Ltd HKEx HK$1.0241 billion T-Cell Immunotherapy 6 Ocumension Therapeutics HKEx HK$1.553 billion Ophthalmology 7   Hepalink HKEx HK$3.8 billion Heparin、Tumour 8 Jhbp (Cy) Holdings Limited HKEx ----- Tumour、Autoimmune disease 9 Everest Medicines Limited HKEx ----- Tumour、Autoimmune disease Cardiorenal diseases Infectious disease 10 Simcere Pharmaceutical Group Limited HKEx -----   Tumour、Central nervous system diseases、Autoimmune disease 11 Jw (Cayman) Therapeutics Co. Ltd HKEx ----- CAR-T 12 Remegen Co. Ltd. HKEx ----- Autoimmune disease、Tumour Ophthalmology 13 Antengene Corporation Limited HKEx ----- Tumour 14 Zelgen STAR Market About ¥2.026 billion Tumour、Hematopathy Hepatobiliary disease 15 Bio-Thera Solutions, Ltd STAR Market About ¥2.0 billion Tumour、Autoimmune disease 16 Sinocelltech Grou Limited STAR Market About ¥1.282 billion Monoclonal Antibody Recombination Protein、Vaccine 17 HitGen Inc. STAR Market About ¥830 million The lead drug 18 Cansino Biologics Inc. STAR Market About ¥5.2 billion Vaccine 19 Sunshine Guojian Pharmaceutical(shanghai) Co. Ltd. STAR Market ¥3.183 billion Antibody 20 Jiangsu Aidea Pharmaceutical Co.,ltd STAR Market ¥839.4 million Antidote、Tumour 21 Junshi BiosciencesCo., Ltd. STAR Market About ¥2.7 billion Tumour、Chronic disease Autoimmune disease 22 Easton BioPharmaceuticals Co.,Ltd STAR Market ¥1.335 billion Combination of generic drug development 23 Frontier Biotechnologies Inc STAR Market ¥1.845 billion AIDS antiviral treatment.  Pain therapy In addition to the companies listed in the above table, other biopharmaceutical companies such as Beijing Science Sun Pharmaceutical Co.,LTD、Changchun BCHT Biotechnology Co and other companies have also submitted IPO applications to the HKEx and the STAR Market